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Some experts have promoted the use of rapid testing for COVID-19. However, with the current
technologies available, continuing to replace laboratory-based, real-time reverse transcription
polymerase chain reaction tests with rapid (point-of-care) tests may lead to an increased number of
false negative tests. Moreover, the more rapid dissemination of false negative results that can occur
with the use of rapid tests for COVID-19 may lead to increased spread of the novel coronavirus
if patients do not understand the concept of false negative tests. One means of combatting this
would be to tell patients who have a “negative” rapid COVID-19 test that their test result was
“indeterminate.” [West J Emerg Med. 2021;22(3)543–546.]

Recent scholarly articles1 and popular media articles2
have pushed for increased availability of rapid (point-of-care)
testing for coronavirus disease 2019 (COVID-19). There
would indeed be many benefits to having an instantaneous
means of accurately determining who has COVID-19 and
who does not. However, with our current technologies and
our current approach to diagnostic testing, we believe that
increasing the use of rapid tests may be harmful as these tests
will speed the dissemination of false negative results.
The criterion standard test for COVID-19 is a (non-rapid)
laboratory-based, real-time reverse transcription polymerase
chain reaction (rRT-PCR) test,3 which is generally performed
as a nasal swab and takes at least 24 hours for results. The
sensitivity of these rRT-PCR tests are about 70% (60-78%),
but they have very high specificity.4 Thus, the issue with rRTPCR tests for COVID-19 is the substantial false negative rate,
which may be even higher if the test is performed by an oral
swab rather than a nasal swab.3 False positive tests are less
common but may occur from contamination of the specimen
or reagents.4 Additionally, some asymptomatic patients who
have a positive rRT-PCR test may be harboring remnants of
severe acute respiratory syndrome coronavirus 2 (SARSCoV-2), but may not be contagious.5 These patients (who are
neither symptomatic nor contagious) should be considered to
have a clinical false positive. No published data have reported
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how often this happens, but for the purposes of the ensuing
calculations, we will assume the specificity of laboratorybased rRT-PCR swab tests is 99.5%.
With regard to rapid tests, there are two types: antigen and
molecular. Antigen tests detect a viral protein, and molecular
tests detect viral RNA. A recent systematic review estimated
that when using the rRT-PCR tests as the criterion standard,
the rapid antigen tests have a sensitivity of 56.2% (95%
confidence interval [CI], 29.5-79.8%) and a specificity of
99.5% (95% CI, 98.1-99.9%) while rapid molecular tests have
a sensitivity of 95.2% (95% CI, 86.7-98.3%) and specificity
98.9% (95% CI, 97.3-99.5%).6 Among the molecular tests
that were assessed, the Xpert Xpress assay (Cepheid Inc.,
Sunnyvale, CA) appears to have the highest sensitivity at
99.4% (95% CI, 98.0-99.8%), which is substantially higher
than the commonly used ID NOW (Abbott Laboratories,
Chicago, IL), which has a sensitivity of 76.8% (95% CI, 72.980.3%). However, the specificity of Xpert Xpress appears to
be a little lower than that of ID NOW at 96.8% (95% CI, 90.699.0%) as compared to 99.6% (95% CI, 98.4-99.9%).6
When interpreting these data, it is important to emphasize
that the criterion standard (rRT-PCR) used for these
calculations also has moderate sensitivity (around 70%)
and imperfect specificity (around 99.5%). Therefore, if the
sensitivity and specificity of a rapid antigen test are 56%
543
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and 99.5%, respectively, compared to rRT-PCR, we would
expect the overall sensitivity to be about 39% and the overall
specificity to be about 99%. Thus, if 1000 people had a rapid
antigen test, and 100 (10%) of them truly had COVID‐19, we
would expect the following:
-39 of the 100 patients with COVID-19 would be
identified with this test (with a true positive result);
-48 patients would test positive for COVID-19, but 9
(18.8%) of those would be false positive results;
- 952 patients would test negative for COVID-19, but 61
(6.4%) of those would be false negative results.
Thus, in the above scenario and detailed in Table 1, nearly
1 in 5 (18.8%) positive tests represents a false positive, and

Table 1. The hypothetical results of 1000 rapid antigen tests for
COVID-19 in a group with a 10% disease prevalence.
Diseased

Non-diseased

True Positives = 39

False Positives = 9

Total Positives = 48

False Negatives =
61

True Negatives =
891

Total Negatives =
952

even more concerning, the majority of patients (61%) with
COVID-19 (n= 100 by design in the example) would have
a negative test (61 false negatives + 39 true negatives = 100
infections). Consequently, we are concerned that without
substantial proviso, rapid antigen tests lack sufficient accuracy
to be used clinically. In particular, we are concerned about
the potential widespread use of the rapid antigen test made
by Abbott Laboratories. This test, which is reported to only
cost $5, recently gathered attention in the popular media
after receiving emergency use status from the US Food and
Drug Administration.7 While there are currently insufficient
data to precisely report this particular test’s sensitivity and
specificity, it is likely similar to the average for antigen
tests mentioned above. However, even if a rapid test that
has a sensitivity similar to that of rRT-PCR is used, we still
believe that replacing the laboratory-based rRT-PCR tests
with rapid tests could be harmful, as rapid tests will likely
increase the spread of SARS-CoV-2 in patients with false
negative results.
Until recently, the impact of false negative COVID-19
tests has likely been dampened both by governmentmandated closures and prolonged wait times for rRT-PCR
test results. With many businesses and schools closed, a
patient with a false negative COVID-19 test had less ability
to widely spread SARS-CoV-2. Additionally, days-long
delays in access to results have been frustrating to patients
and physicians. However, patients’ isolation behavior
is likely stricter during the waiting period for results
than following a negative result. Because the period of
Western Journal of Emergency Medicine

preventable transmission for SARS-CoV-2 (typically less
than 10 days following initiation of symptoms for mild
to moderate COVID-19) is coincident with most waiting
periods for results, it seems likely that the delay in results
has offered some measure of unrecognized protection. This
means that with the increasing use of rapid COVID-19 tests,
transmission of SARS-CoV-2 could actually increase. More
immediate results mean more immediate false “negatives”
and, likely, less concerted self-isolation behavior.
The idea that the wait time for the results of COVID-19
tests is protective is supported by one survey study that asked
respondents to describe their isolation behaviors during a
hypothetical outbreak involving a potentially fatal contagious
respiratory illness. Respondents who were uncertain of their
own transmissibility to vulnerable individuals reported they
would engage in social isolation behaviors at the same rate
that they reported for scenarios in which they knew they
would infect vulnerable individuals.8 Therefore, the wait
period for the results of an rRT-PCR test likely produces a
healthy uncertainty that is more associated with appropriate
isolation behavior than the behavior after a (potentially false)
negative test result.
We believe the main reason for this is that most patients
and some healthcare professionals do not understand the
concept of false negative tests. We fear that patients who have
false negative tests may immediately return to work or school
or get on a plane, even if symptomatic and even if counseled
to stay home until symptoms resolve. Worse, some healthcare
professionals may not fully understand how to incorporate the
sensitivity of a diagnostic test into their decision-making and
may not provide appropriate counsel to patients with negative
test results. Indeed, previous work has demonstrated that both
physicians and patients have trouble interpreting and applying
healthcare statistics.9
Even if all physicians knew how to appropriately
counsel patients with negative COVID-19 tests, the current
testing strategy for COVID-19 often bypasses physician
assessment of the patient, compounding the problem of
false negative tests. Medical tests have traditionally been
ordered and interpreted by physicians. However, tests for
COVID-19 can now be done at a drugstore, in a drive-thru
testing site, or at home without a healthcare professional’s
involvement. While increased access to testing is a good
thing, misinterpretation of test results is dangerous.
Many tests for COVID-19 are being done without any
consideration for the pretest probability, without which
we cannot properly assess the results. Most people who
get the test just assume that a positive test means they
have COVID-19, while a negative test means they do not.
With no healthcare professional to counsel the patient, the
patient will not know any better.
Now, reconsider the scenario above where 1000 rapid
antigen tests were performed on a population where 10%
actually had COVID-19. In an ideal world, all of the 61
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patients who had false negative results would remain in
quarantine despite their negative test results, and they would
not spread SARS-CoV-2 to anyone new. However, suppose
20% (12 patients) of those 61 patients with a false negative
test return to work, school, or social situations early because
they believe they do not have COVID-19. If six of these 12
patients spreads SARS-CoV-2 to just one new person that
would not have been exposed to the virus had the patient
remained in quarantine for 2-3 more days, then the transition
from rRT-PCR tests to rapid antigen tests accounts for six new
cases of COVID-19 in this group of 1000 tested patients. Over
hundreds of thousands or millions of rapid antigen tests, the
increased spread of SARS-CoV-2 through this mechanism
could be striking.
At this point, rapid testing for COVID-19 is already
widely used. The lack of accuracy of the tests seems to be
less important to some decisionmakers than the fact that
they give a result quickly. In a few special circumstances
where repeated tests for COVID-19 are performed on
asymptomatic individuals, such as testing done by the
National Football League, rapid testing may be preferred
to laboratory-based testing for logistical reasons. However,
in typical healthcare settings, rapid tests are not optimal
and must be used cautiously. Therefore, as a means to
reduce the spreading of SARS-CoV-2 from patients who
have had “negative” rapid COVID-19 tests, we recommend
two potential solutions. First, negative results of rapid
tests should be called “indeterminate.” This is in fact more
accurate than saying the test was negative (since possibly
over 50% of patients with COVID-19 will have a false
negative). For outpatients with possible COVID-19, this
would serve as a constant reminder that they should remain
in self-isolation until their symptoms resolve even if their
test is negative.
Second, in cases where patients are being admitted to the
hospital with a clinical presentation suggestive of COVID-19,
the patient should continue to be isolated even if they have
a negative rapid test. For these patients, additional testing
for COVID-19 should be considered, and for some of these
patients, a computed tomography (CT) of the chest should
be performed. Notably, some society guidelines recommend
against the use of CT of the chest for the diagnosis of
COVID-19, and the harms of CT with regard to radiation and
cost are important to consider.10, 11 However, the combination
of rRT-PCR and CT provides a very high sensitivity (about
97%) for COVID-194; thus, the selective use of this strategy
could reduce the potential harms of false negative tests
discussed above.
In summary, regardless of the type of test used for
virologic confirmation of SARS-CoV-2, there are a
substantial number of false negative tests. Rapid tests,
especially rapid antigen tests, likely have even higher
numbers of false negatives. Therefore, policies for
quarantine and isolation that rely solely on the results
Volume 22, no. 3: May 2021

of a rapid test are bound to result in misdiagnosis and
increased viral transmission. Informing patients that their
rapid COVID-19 test was negative could result in less
self-isolation and increased viral spread. If rapid tests are
used, we recommend that negative results instead be called
“indeterminate” to remind patients that a negative test does
not mean they do not have COVID-19.
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